Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

A method to summarize toxicity in cancer randomized clinical trials.

Carbini M, Suárez-Fariñas M, Maki RG.

Clin Cancer Res. 2018 May 8. pii: clincanres.3314.2017. doi: 10.1158/1078-0432.CCR-17-3314. [Epub ahead of print]

PMID:
29739789
2.

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran R, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H.

J Clin Oncol. 2018 Apr 1;36(10):1020-1044. doi: 10.1200/JCO.2017.77.0446. Epub 2018 Jan 30.

PMID:
29380678
3.

Sarcoma: The Merging of Science and Clinical Care.

Schwartz GK, Maki RG.

J Clin Oncol. 2018 Jan 10;36(2):99-100. doi: 10.1200/JCO.2017.76.9091. Epub 2017 Dec 8. No abstract available.

PMID:
29220300
4.

Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition.

Pang A, Carbini M, Moreira AL, Maki RG.

J Clin Oncol. 2018 Jan 10;36(2):210-216. doi: 10.1200/JCO.2017.74.9523. Epub 2017 Dec 8.

PMID:
29220296
5.

Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment.

Khan JA, Maki RG, Ravi V.

J Clin Oncol. 2018 Jan 10;36(2):194-201. doi: 10.1200/JCO.2017.74.9812. Epub 2017 Dec 8.

PMID:
29220293
6.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S.

Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jan;19(1):e8.

PMID:
28988646
7.

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.

Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S.

J Clin Oncol. 2017 Oct 20;35(30):3433-3439. doi: 10.1200/JCO.2016.71.6605. Epub 2017 Aug 30.

PMID:
28854066
8.

Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.

Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A.

Oncologist. 2018 Jan;23(1):62-70. doi: 10.1634/theoncologist.2017-0161. Epub 2017 Jul 28.

PMID:
28754721
9.

Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model.

Demicco EG, Wagner MJ, Maki RG, Gupta V, Iofin I, Lazar AJ, Wang WL.

Mod Pathol. 2017 Oct;30(10):1433-1442. doi: 10.1038/modpathol.2017.54. Epub 2017 Jul 21.

PMID:
28731041
10.

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD.

Gynecol Oncol. 2017 Sep;146(3):531-537. doi: 10.1016/j.ygyno.2017.06.018. Epub 2017 Jun 24.

PMID:
28651804
11.

Targeting sarcoma tumor-initiating cells through differentiation therapy.

Han D, Rodriguez-Bravo V, Charytonowicz E, Demicco E, Domingo-Domenech J, Maki RG, Cordon-Cardo C.

Stem Cell Res. 2017 May;21:117-123. doi: 10.1016/j.scr.2017.04.004. Epub 2017 Apr 13.

12.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.

JAMA Oncol. 2017 Jul 1;3(7):944-952. doi: 10.1001/jamaoncol.2016.6728.

13.

Treatment of soft tissue sarcoma: a focus on earlier stages.

Gronchi A, Maki RG, Jones RL.

Future Oncol. 2017 Jan;13(1s):13-21. Review.

PMID:
27918202
14.

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P.

J Clin Oncol. 2016 Nov 10;34(32):3898-3905. doi: 10.1200/JCO.2016.67.6684. Epub 2016 Sep 30.

PMID:
27621408
15.

Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.

Martínez-Marín V, Maki RG.

Gastroenterol Clin North Am. 2016 Sep;45(3):477-86. doi: 10.1016/j.gtc.2016.04.006. Review.

PMID:
27546844
16.

Monogenic and polygenic determinants of sarcoma risk: an international genetic study.

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM; International Sarcoma Kindred Study.

Lancet Oncol. 2016 Sep;17(9):1261-71. doi: 10.1016/S1470-2045(16)30147-4. Epub 2016 Aug 4.

PMID:
27498913
17.

Development and clinical application of an integrative genomic approach to personalized cancer therapy.

Uzilov AV, Ding W, Fink MY, Antipin Y, Brohl AS, Davis C, Lau CY, Pandya C, Shah H, Kasai Y, Powell J, Micchelli M, Castellanos R, Zhang Z, Linderman M, Kinoshita Y, Zweig M, Raustad K, Cheung K, Castillo D, Wooten M, Bourzgui I, Newman LC, Deikus G, Mathew B, Zhu J, Glicksberg BS, Moe AS, Liao J, Edelmann L, Dudley JT, Maki RG, Kasarskis A, Holcombe RF, Mahajan M, Hao K, Reva B, Longtine J, Starcevic D, Sebra R, Donovan MJ, Li S, Schadt EE, Chen R.

Genome Med. 2016 Jun 1;8(1):62. doi: 10.1186/s13073-016-0313-0.

18.

Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review.

Pang A, Carbini M, Maki RG.

JAMA Oncol. 2016 Jul 1;2(7):941-7. doi: 10.1001/jamaoncol.2016.0241. Review.

PMID:
27148906
19.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR.

Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10.

PMID:
26874885
20.
21.

Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches.

Ang C, Maki RG.

Oncol Ther. 2016;4(1):1-16. doi: 10.1007/s40487-015-0014-7. Epub 2016 Jan 8. Review.

22.

Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation.

Brohl AS, Demicco EG, Mourtzikos K, Maki RG.

Clin Sarcoma Res. 2015 Sep 21;5:21. doi: 10.1186/s13569-015-0036-9. eCollection 2015.

23.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR.

J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14.

24.

Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy.

Noujaim J, Thway K, Bajwa Z, Bajwa A, Maki RG, Jones RL, Keller C.

Front Oncol. 2015 Aug 17;5:186. doi: 10.3389/fonc.2015.00186. eCollection 2015. Review.

25.

Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas.

Gounder M, Desai V, Kuk D, Agaram N, Arcila M, Durham B, Keohan ML, Dickson MA, D'Angelo SP, Shukla N, Moskowitz C, Noy A, Maki RG, Herrera DA, Sanchez A, Krishnan A, Pourmoussa A, Qin LX, Tap WD.

Eur J Cancer. 2015 Nov;51(16):2413-22. doi: 10.1016/j.ejca.2015.06.109. Epub 2015 Aug 19.

26.

Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma.

Attia S, Okuno SH, Robinson SI, Webber NP, Indelicato DJ, Jones RL, Bagaria SP, Jones RL, Sherman C, Kozak KR, Cortese CM, McFarland T, Trent JC, Maki RG.

Rare Tumors. 2015 May 21;7(2):5992. doi: 10.4081/rt.2015.5992. eCollection 2015 May 5.

27.

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.

Dickson MA, D'Adamo DR, Keohan ML, D'Angelo SP, Carvajal RD, Gounder MM, Maki RG, Qin LX, Lefkowitz RA, McKennon OR, Hirst CM, Schwartz GK, Tap WD.

Sarcoma. 2015;2015:532478. doi: 10.1155/2015/532478. Epub 2015 May 14.

28.

Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.

Maki RG, Blay JY, Demetri GD, Fletcher JA, Joensuu H, Martín-Broto J, Nishida T, Reichardt P, Schöffski P, Trent JC.

Oncologist. 2015 Jul;20(7):823-30. doi: 10.1634/theoncologist.2014-0471. Epub 2015 Jun 12. Review.

29.

Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery.

Joensuu H, Martin-Broto J, Nishida T, Reichardt P, Schöffski P, Maki RG.

Eur J Cancer. 2015 Aug;51(12):1611-7. doi: 10.1016/j.ejca.2015.05.009. Epub 2015 May 25. Review.

30.

GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer.

Cioffi A, Maki RG.

J Clin Oncol. 2015 Jun 1;33(16):1849-54. doi: 10.1200/JCO.2014.59.7344. Epub 2015 Apr 27. Review.

PMID:
25918303
31.

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.

Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalcberg J, Verweij J, Casali PG, Maki RG, Cioffi A, Mcarthur G, Lord SJ, Yip D, Kanjanapan Y, Rutkowski P.

Eur J Cancer. 2015 May;51(7):852-60. doi: 10.1016/j.ejca.2015.02.015. Epub 2015 Mar 19.

PMID:
25801699
32.

Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma.

Brohl AS, Li L, Andikyan V, Običan SG, Cioffi A, Hao K, Dudley JT, Ascher-Walsh C, Kasarskis A, Maki RG.

Oncologist. 2015 Apr;20(4):433-9. doi: 10.1634/theoncologist.2014-0361. Epub 2015 Mar 12.

33.

Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors.

Palmerini E, Staals EL, Maki RG, Pengo S, Cioffi A, Gambarotti M, Picci P, Daolio PA, Parafioriti A, Morris C, Antonescu CR, Gronchi A, Casali PG, Donati DM, Ferrari S, Stacchiotti S.

Eur J Cancer. 2015 Jan;51(2):210-7. doi: 10.1016/j.ejca.2014.11.001. Epub 2014 Nov 24.

PMID:
25465190
34.

Cutaneous metastasis of a perivascular epithelioid cell tumor.

Wu J, Maki RG, Noroff JP, Silvers DN.

Cutis. 2014 Apr;93(4):E20-1. No abstract available.

PMID:
24818188
35.

A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.

Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Geoerger B, Ganjoo K, Marina N, Blay JY, Schuetze SM, Chow WA, Helman LJ.

Cancer. 2014 Aug 15;120(16):2448-56. doi: 10.1002/cncr.28728. Epub 2014 May 2.

36.

Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?

Farid M, Ahn L, Brohl A, Cioffi A, Maki RG.

Sarcoma. 2014;2014:617102. doi: 10.1155/2014/617102. Epub 2014 Feb 13.

37.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP.

J Clin Oncol. 2014 May 20;32(15):1563-70. doi: 10.1200/JCO.2013.51.2046. Epub 2014 Mar 17. Erratum in: J Clin Oncol. 2014 Oct 20;32(30):3462.

38.

Malignant peripheral nerve sheath tumors.

Farid M, Demicco EG, Garcia R, Ahn L, Merola PR, Cioffi A, Maki RG.

Oncologist. 2014 Feb;19(2):193-201. doi: 10.1634/theoncologist.2013-0328. Epub 2014 Jan 27. Review.

39.

International expert opinion on patient-tailored management of soft tissue sarcomas.

Blay JY, Sleijfer S, Schöffski P, Kawai A, Brodowicz T, Demetri GD, Maki RG.

Eur J Cancer. 2014 Mar;50(4):679-89. doi: 10.1016/j.ejca.2013.11.011. Epub 2013 Nov 29. Review.

PMID:
24295638
40.

Advanced chondrosarcomas: role of chemotherapy and survival.

Italiano A, Mir O, Cioffi A, Palmerini E, Piperno-Neumann S, Perrin C, Chaigneau L, Penel N, Duffaud F, Kurtz JE, Collard O, Bertucci F, Bompas E, Le Cesne A, Maki RG, Ray Coquard I, Blay JY.

Ann Oncol. 2013 Nov;24(11):2916-22. doi: 10.1093/annonc/mdt374. Epub 2013 Oct 7.

41.

Angiosarcomas and other sarcomas of endothelial origin.

Cioffi A, Reichert S, Antonescu CR, Maki RG.

Hematol Oncol Clin North Am. 2013 Oct;27(5):975-88. doi: 10.1016/j.hoc.2013.07.005. Epub 2013 Aug 26. Review.

PMID:
24093171
42.

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.

DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology.

Ann Surg. 2013 Sep;258(3):422-9. doi: 10.1097/SLA.0b013e3182a15eb7.

43.

Preliminary results of high-dose single-fraction radiotherapy for the management of chordomas of the spine and sacrum.

Yamada Y, Laufer I, Cox BW, Lovelock DM, Maki RG, Zatcky JM, Boland PJ, Bilsky MH.

Neurosurgery. 2013 Oct;73(4):673-80; discussion 680. doi: 10.1227/NEU.0000000000000083.

PMID:
23842548
44.

Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7.

Maki RG, Moraco N, Antonescu CR, Hameed M, Pinkhasik A, Singer S, Brennan MF.

Ann Surg Oncol. 2013 Oct;20(11):3377-83. doi: 10.1245/s10434-013-3052-0. Epub 2013 Jun 18.

45.

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.

Maki RG, Jungbluth AA, Gnjatic S, Schwartz GK, D'Adamo DR, Keohan ML, Wagner MJ, Scheu K, Chiu R, Ritter E, Kachel J, Lowy I, Old LJ, Ritter G.

Sarcoma. 2013;2013:168145. doi: 10.1155/2013/168145. Epub 2013 Feb 27.

46.

Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival.

Garbay D, Maki RG, Blay JY, Isambert N, Piperno Neumann S, Blay C, Zanardi E, Boudou-Rouquette P, Bozec L, Duffaud F, Bertucci F, Italiano A.

Ann Oncol. 2013 Jul;24(7):1924-30. doi: 10.1093/annonc/mdt059. Epub 2013 Mar 13.

PMID:
23493135
47.

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG.

Lancet Oncol. 2013 Apr;14(4):371-82. doi: 10.1016/S1470-2045(13)70049-4. Epub 2013 Mar 8.

48.

Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions.

Palmerini E, Maki RG, Staals EL, Alberghini M, Antonescu CR, Ferrari C, Ruggieri P, Mavrogenis A, Bertoni F, Cesari M, Paioli A, Marchesi E, Picci P, Ferrari S.

Am J Clin Oncol. 2014 Dec;37(6):528-34. doi: 10.1097/COC.0b013e31827defa1.

49.

Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer.

Wagner MJ, Maki RG.

Front Oncol. 2013 Feb 4;3:9. doi: 10.3389/fonc.2013.00009. eCollection 2013.

50.

Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).

Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, George S, Soslow RA, Baker LH.

Cancer. 2013 Apr 15;119(8):1555-61. doi: 10.1002/cncr.27942. Epub 2013 Jan 18.

Supplemental Content

Support Center